Skip to main navigation Skip to search Skip to main content

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K

  • Afsar Ali Mian
  • , Isabella Haberbosch
  • , Hazem Khamaisie
  • , Abed Agbarya
  • , Larissa Pietsch
  • , Elizabeh Eshel
  • , Dally Najib
  • , Claudia Chiriches
  • , Oliver Gerhard Ottmann
  • , Oliver Hantschel
  • , Ricardo M. Biondi
  • , Martin Ruthardt
  • , Jamal Mahajna

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K'. Together they form a unique fingerprint.
Sort by

Keyphrases

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science